$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Cabozantinib capsule specifications and instructions for use
2026-02-01 22:25:32
Check Details
What type of drug is lorlatinib/lorlatinib?
2026-02-01 22:25:32
Check Details
How long does it take to see the effect after taking Pralsetinib?
2026-02-01 22:25:32
Check Details
Is capmatinib included in the reimbursement scope of my country's medical insurance?
2026-02-01 22:25:32
Check Details
Can Sotorasib be used in combination with immunological drugs?
2026-02-01 22:25:32
Check Details
Can Adagrasib be used in combination with other targeted drugs?
2026-02-01 22:25:32
Check Details
Is larotrectinib suitable for patients with brain metastases to continue taking?
2026-02-01 22:25:32
Check Details
Is Selinexor and Bortezomib better together?
2026-02-01 22:25:32
Check Details
What are the risks and preventive measures for relapse after discontinuation of Vigabatrin (vigabatrin)?
2026-02-01 22:25:32
Check Details
How to monitor treatment response and evaluate efficacy of Mobotinib
2026-02-01 22:25:32
Check Details
Discussion on the risk of recurrence after discontinuation of Tepotinib and the safe withdrawal plan
2026-02-01 22:25:32
Check Details
Introduction to the risk of liver function injury and monitoring plan of Regorafenib
2026-02-01 22:25:32
Check Details
1
2
...
1636
1637
1638
1639
1640
1641
1642
...
10213
10214
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Pretomanid for Drug-Resistant TB: Risks and Management of 3-Year Treatment
2
SKYSCRAPER-02C Study: New Hope for Extensive-Stage Small Cell Lung Cancer Treatment
3
LPCAT3: The Key Player in MASH Progression to Hepatocellular Carcinoma
4
Tucatinib (Tukysa): A Precision Medicine for HER2-Positive Breast & Colorectal Cancer
5
Venetoclax Therapy Guidelines: Balancing Precision Targeting with Risk Management
6
Global Breakthrough: Pralsetinib - Precision Medicine for RET Mutation-Driven Cancers
7
A Comprehensive Guide to Benralizumab Adverse Reactions: Prevention and Management
8
Lemborexant: A Dual Orexin Receptor Antagonist Revolutionizing Insomnia Treatment
9
Breztri Aerosphere Approved by US FDA for Maintenance Treatment of Asthma in Patients Aged 12 Years and Older
10
Datopotamab Deruxtecan as First-Line Treatment for Advanced Triple-Negative Breast Cancer: Full Interpretation of the Phase III TROPION-Breast02 Trial
11
Elacestrant: Precision Therapy for ESR1-Mutant Resistant HR+/HER2- Advanced Breast Cancer
12
Vibegron 2026 Research Updates: New Evidence for Overactive Bladder Treatment